<qa>  What is the effect of OSI-774 to the combination of paclitaxel andIII. To determine the effect of the addition of OSI-774 Tarceva to the combination of paclitaxel and carboplatin on progression-free interval in patients with Stage III optimally cytoreduced stratum 1 and Stage III suboptimally cytoreduced or Stage IV stratum 2 ovarian or primary peritoneal carcinomas when used as front line therapy. 